NCT07743151PHASE1RecruitingAccepts Healthy Volunteers
A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
Merck Sharp & Dohme LLC
Start Date
9/10/2026
Completion Date
2/5/2027
Summary
The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections. Researchers also want to learn about the safety of MK-1406 and if people tolerate it.
Eligibility Criteria
Age Range: 18 years to 64 years
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
* Is in good health
* Has body mass index (BMI) 18.0 to 32.0 kg/m\^2
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
* History of clinically significant endocrine, Gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* History of cancer (malignancy)
Interventions
DRUG
MK-1406
Conditions
Healthy
Locations
Research Centers of America ( Hollywood ) ( Site 0008)
Hollywood, Florida 33024
United States
QPS-MRA, LLC ( Site 0007)
South Miami, Florida 33143
United States
Hassman Research Institute Marlton Site ( Site 0001)
Marlton, New Jersey 08053
United States
Velocity Clinical Research, Cleveland ( Site 0005)
Cleveland, Ohio 44122
United States